Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.43 Insider Own8.59% Shs Outstand48.08M Perf Week11.71%
Market Cap23.44M Forward P/E- EPS next Y-0.45 Insider Trans2.36% Shs Float44.64M Perf Month5.96%
Income-20.77M PEG- EPS next Q-0.12 Inst Own8.85% Short Float / Ratio1.04% / 3.62 Perf Quarter-21.57%
Sales0.19M P/S123.39 EPS this Y-10.00% Inst Trans-3.77% Short Interest0.46M Perf Half Y7.87%
Book/sh0.45 P/B1.07 EPS next Y-2.27% ROA-56.04% Target Price3.83 Perf Year18.52%
Cash/sh0.46 P/C1.05 EPS next 5Y25.00% ROE-63.63% 52W Range0.29 - 0.84 Perf YTD53.90%
Dividend- P/FCF- EPS past 5Y49.85% ROI-89.76% 52W High-42.58% Beta-0.03
Dividend %- Quick Ratio4.82 Sales past 5Y-14.84% Gross Margin-140.93% 52W Low64.95% ATR0.04
Employees24 Current Ratio4.82 Sales Q/Q119.05% Oper. Margin-12160.01% RSI (14)56.22 Volatility7.29% 9.79%
OptionableNo Debt/Eq0.03 EPS Q/Q-21.01% Profit Margin-10764.25% Rel Volume0.67 Prev Close0.47
ShortableYes LT Debt/Eq0.02 EarningsNov 15 BMO Payout- Avg Volume128.06K Price0.48
Recom1.00 SMA206.60% SMA503.96% SMA200-7.30% Volume86,264 Change2.13%
Nov-28-23 04:30PM
Nov-27-23 09:00PM
Nov-21-23 12:00PM
Nov-16-23 08:45AM
Nov-15-23 07:30AM
10:00AM Loading…
Nov-14-23 10:00AM
Nov-09-23 08:05AM
Nov-08-23 08:45AM
Nov-06-23 09:25AM
Oct-30-23 08:55AM
Oct-17-23 08:45AM
Sep-22-23 09:05AM
Sep-11-23 01:00PM
Sep-05-23 09:05AM
Aug-23-23 08:00AM
06:45AM Loading…
Aug-15-23 06:45AM
Aug-09-23 09:05AM
Aug-08-23 08:05AM
Jul-18-23 07:30PM
Jul-10-23 08:05AM
Jul-05-23 08:35AM
Jun-27-23 11:16AM
Jun-14-23 08:45AM
Jun-12-23 08:45AM
Jun-07-23 07:11PM
May-15-23 08:45AM
May-09-23 08:50AM
03:56PM Loading…
Apr-20-23 03:56PM
Apr-12-23 08:35AM
Apr-10-23 07:30AM
Apr-04-23 08:45AM
Apr-03-23 06:30AM
Mar-30-23 08:45AM
Mar-27-23 09:05AM
Mar-16-23 08:45AM
Mar-08-23 08:45AM
Mar-06-23 08:45AM
Feb-28-23 08:45AM
Feb-17-23 08:55AM
Jan-17-23 08:45AM
Jan-11-23 01:00PM
Jan-09-23 08:05AM
Jan-05-23 08:45AM
Dec-12-22 09:00AM
Dec-08-22 08:05AM
Dec-02-22 10:45AM
Nov-15-22 07:00AM
Nov-14-22 07:00AM
Nov-09-22 09:00AM
Nov-03-22 12:34PM
Nov-02-22 07:05AM
Nov-01-22 05:19PM
Oct-31-22 07:30AM
Oct-26-22 05:12PM
Oct-24-22 08:30AM
Oct-13-22 10:32AM
Oct-12-22 04:32PM
Sep-21-22 08:45AM
Sep-19-22 08:05AM
Sep-07-22 07:25AM
Sep-06-22 07:30AM
Aug-30-22 07:30AM
Aug-18-22 09:05AM
Aug-16-22 04:05PM
Aug-15-22 04:05PM
Jul-28-22 09:10AM
Jul-21-22 12:26PM
Jul-20-22 08:05AM
Jul-18-22 08:00AM
Jul-14-22 08:05AM
Jun-21-22 08:35AM
Jun-13-22 08:05AM
May-19-22 08:00AM
May-18-22 08:00AM
May-16-22 07:05AM
May-12-22 08:05AM
Apr-21-22 08:05AM
Apr-12-22 07:47AM
Apr-11-22 09:20AM
Apr-04-22 06:26PM
Mar-31-22 04:05PM
Mar-30-22 07:00AM
Mar-29-22 10:17PM
Mar-28-22 07:35AM
Mar-24-22 10:10AM
Mar-23-22 08:05AM
Mar-21-22 08:00AM
Mar-16-22 07:05AM
Mar-09-22 07:35AM
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Equels Thomas KCEO & PresidentNov 27Buy0.4433,86115,000640,697Nov 27 12:56 PM
Equels Thomas KCEO & PresidentSep 29Buy0.4422,67610,000606,836Sep 29 03:29 PM
Equels Thomas KCEO & PresidentAug 25Buy0.678,2225,501584,160Aug 25 02:26 PM
Equels Thomas KCEO & PresidentAug 24Buy0.6714,99310,000575,938Aug 24 01:52 PM
Equels Thomas KCEO & PresidentJul 17Buy0.5916,95010,000560,945Jul 17 07:20 PM
Equels Thomas KCEO & PresidentJan 03Buy0.31161,29150,000543,995Jan 04 07:30 AM
Rodino Peter W IIICOO, Secretary, Gen. CounselJan 03Buy0.3180,64625,000143,839Jan 04 07:30 AM
APPELROUTH STEWARTDirectorJan 03Buy0.3180,64625,000217,063Jan 04 07:30 AM